

AD \_\_\_\_\_

Award Number: DAMD17-03-1-0655

TITLE: Obesity and Postmenopausal Breast Cancer:  
Leptin-Estrogen Cross-Talk

PRINCIPAL INVESTIGATOR: Eva Surmacz, Ph.D.

CONTRACTING ORGANIZATION: Thomas Jefferson University  
Philadelphia, Pennsylvania 19107-5567

REPORT DATE: October 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050218 096

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

**1. AGENCY USE ONLY**  
(Leave blank)**2. REPORT DATE**  
October 2004**3. REPORT TYPE AND DATES COVERED**  
Final (1 Sep 2003 - 30 Sep 2004)**4. TITLE AND SUBTITLE**Obesity and Postmenopausal Breast Cancer:  
Leptin-Estrogen Cross-Talk**5. FUNDING NUMBERS**

DAMD17-03-1-0655

**6. AUTHOR(S)**

Eva Surmacz, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**Thomas Jefferson University  
Philadelphia, Pennsylvania 19107-5567**E-Mail:** Eva.surmacz@jefferson.edu**8. PERFORMING ORGANIZATION  
REPORT NUMBER****9. SPONSORING / MONITORING  
AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING  
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

**12b. DISTRIBUTION CODE****13. ABSTRACT (Maximum 200 Words)**

Obesity is a risk factor for breast cancer development in postmenopausal women and correlates with shorter disease-free and overall survival in breast cancer patients, regardless of menopausal status. Adipose tissue is a major source of leptin, a pluripotent cytokine regulating energy balance and controlling different processes in peripheral tissues, including breast cancer cell growth. In this work, we asked whether leptin can stimulate breast cancer cell growth and counteract anti-tumorigenic activities of the antiestrogen ICI 182,780 (ICI). MCF-7 estrogen receptor alpha (ERa)-positive breast cancer cells were used as a model.

MCF-7 cells were found to express the signaling form of the leptin receptor and respond to leptin with cell growth and activation the STAT3, ERK1/2, and Akt/GSK3/pRb pathways. As expected, the exposure of cells to 10 nM ICI blocked cell proliferation, induced rapid ERa degradation, inhibited nuclear expression of ERa, and reduced ERa-dependent transcription from estrogen response element-containing promoters. All these effects of ICI were significantly attenuated by simultaneous treatment of cells with 100 ng/ml leptin. We concluded that leptin interferes with the effects of ICI on ERa in breast cancer cells. Thus, high leptin levels in obese breast cancer patients might contribute to the development of antiestrogen-resistance.

**14. SUBJECT TERMS**

Obesity, breast cancer, antiestrogen resistance, estrogen receptor

**15. NUMBER OF PAGES**

22

**16. PRICE CODE****17. SECURITY CLASSIFICATION  
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION  
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION  
OF ABSTRACT**

Unclassified

**20. LIMITATION OF ABSTRACT**

Unlimited

## Table of Contents

<b>Cover</b>	<b>1</b>
<b>SF 298</b>	<b>2</b>
<b>Introduction</b>	<b>4</b>
<b>Body</b>	<b>5</b>
<b>Key Research Accomplishments</b>	<b>8</b>
<b>Reportable Outcomes</b>	<b>8</b>
<b>Conclusions</b>	<b>9</b>
<b>References</b>	<b>9</b>

### Appendices

**Manuscript:** Garofalo, C., Sisci, D., Surmacz, E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin. Cancer Res., in press, October 1, 2004.

## INTRODUCTION

In the United States over 60% of population is overweight or obese. Obesity is an underlying cause of more than 30 different diseases, including certain types of cancer. Numerous epidemiological studies documented that obesity is a risk factor for postmenopausal breast cancer (1-4). Furthermore, increased body weight and body mass index (BMI) have been associated with shorter disease-free and overall survival in breast cancer patients, regardless of age and menopausal status (4). Some studies also suggested that obesity can reduce the efficacy of anti-breast cancer chemotherapy (5). In animal models, high adiposity has been linked with increased incidence of spontaneous and chemically induced mammary tumors (6-9).

Human obesity is associated with increased levels of leptin, a 16 kDa circulating hormone controlling food intake and energy balance by providing signals to the hypothalamus (10). In addition to its central nervous system (CNS) activities, leptin regulates multiple processes in peripheral tissues, including hematopoiesis, immune responses, puberty, pregnancy, and lactation (10-14). In cellular models, leptin has been shown to activate proliferation, angiogenesis, motility and invasion (10, 15-22). The major source of leptin is adipose tissue; however, leptin can be produced by other organs, including the mammary gland (10-12).

The activities of leptin are mediated through the transmembrane leptin receptor (ObR) (23). In human tissues, at least four isoforms of ObR with different C-terminal cytoplasmic domains have been described (24). The full (long) form of ObR (ObR<sub>L</sub>) is 1165 aa long (~150-190 kDa) and contains extracellular, transmembrane, and intracellular domains. The extracellular domain binds ligand, while intracellular tail recruits and activates signaling substrates. Only ObR<sub>L</sub> has a full signaling potential, while the shorter ObR isoforms have diminished or abolished signaling capability (25-28). The signaling pathways known to be activated by ObR<sub>L</sub> include the classic cytokine JAK2/STAT3 pathway, the Ras/ERK signaling cascade, the kinases PI-3K, Akt, p38, and PKC as well as nitric oxide and phospholipase C $\gamma$  (25-27). Ultimately, induction of ObR<sub>L</sub> can activate the expression of several genes involved in cell proliferation, including *c-fos*, *c-jun*, *jun B*, *egr-1*, *socs3* (25, 26).

Although leptin is necessary for normal mammary gland development in rodents and humans (11, 12, 18, 29), recent studies suggested that the hormone might be involved in mammary carcinogenesis (18-22, 30, 31). Notably, leptin (31) and ObR (20) have been detected in human breast cancer specimens. In breast cancer cell lines T47D and MCF-7, leptin has been shown to stimulate DNA synthesis and cell growth acting through the STAT3 and ERK1/2 signaling pathways (18-20, 22). Leptin has also been shown to induce transformation (anchorage-independent growth) of cancer but not normal breast epithelial cells (18). Finally, leptin-deficient mice have decreased incidence of spontaneous and oncogene-induced mammary tumors (30).

The possible impact of leptin produced in mammary tissue on breast cancer development is yet unknown. The role of circulating leptin remains unclear, with

clinical studies reporting either positive (32), negative (33), or no association (34) of serum leptin levels with breast cancer.

In addition to leptin, adipose tissue is a source of estrogens produced, via aromatase conversion, from androstenedione in postmenopausal women (35). Recent studies suggest that leptin and estrogen systems are involved in functional crosstalk. For instance, leptin has been shown to modulate, either positively (36, 37, 38) or negatively (39, 40) aromatase activity. Reciprocally, 17- $\beta$ -estradiol (E2) has been found to upregulate leptin mRNA and protein synthesis in adipocytes (41). E2 can also modulate ObR expression (42), possibly through the putative estrogen responsive element (ERE) in the *ObR* gene promoter (43).

In this study, we explored a new aspect of leptin/estrogen crosstalk. Specifically, we asked whether leptin can interfere with anti-tumorigenic effects of the antiestrogen ICI 182,780 (ICI). ICI (Faslodex, fulvestrant, AstraZeneca), which induces estrogen receptor  $\alpha$  (ER $\alpha$ ) degradation through ubiquitin-mediated mechanism (44-47), is currently used for treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following other hormonal therapy (44).

## TECHNICAL REPORT

During the reporting performance period we addressed the role of leptin in breast cancer cells, focusing on leptin-estrogen cross-talk, as proposed in SOW. The following experiments have been performed:

### 1. ObR<sub>i</sub> is expressed in ER $\alpha$ -positive breast cancer cell lines.

To study possible effects of leptin on ICI action, we first assessed the expression of ObR<sub>i</sub>, a signaling form of ObR, in a different breast cancer cell lines. Several ObR isoforms (~190-150 kDa) were detected in ER $\alpha$ -positive and ER $\alpha$ -negative breast cancer cells by WB (Fig. 1, Garofalo et al., Appendix). Notably, the greatest expression of ObR<sub>i</sub> 190 kDa was found in ER $\alpha$ -positive cell lines, MCF-7 and T47D. The shorter isoforms of ObR were abundant in ER $\alpha$ -negative cells (Fig. 1). For further experiments, we selected MCF-7 cells because they are E2- and ICI-responsive and express high levels of ObR<sub>i</sub>.

### 2. Leptin induces multiple signaling pathways in MCF-7 cells.

We examined leptin effects on the activation of different ObR<sub>i</sub> signaling pathways in MCF-7 cells. In addition to ObR<sub>i</sub> pathways known to be induced in breast cancer cells, i.e., STAT3 and ERK1/2 (18-20), we studied whether leptin can activate Akt/GSK3 antiapoptotic signaling and whether it can phosphorylate (and thereby block) a key cell cycle inhibitor, pRb.

The stimulation of ObR<sub>i</sub> by leptin was assessed at different time points, from 5

min to 24 h. The stimulation of MCF-7 cells with leptin induced multiple signaling elements, including STAT3, ERK1/2, Akt, GSK3b (Fig. 2, Garofalo et al., Appendix). These leptin effects coincided with the phosphorylation of pRb on Ser<sup>795</sup> (Fig. 2B).

### **3. Leptin stimulates the proliferation of MCF-7 cells and interferes with ICI-dependent growth inhibition.**

The mitogenic effects of leptin at doses 1-1000 ng/ml were studied in MCF-7 cells at 1 and 3 days of treatment (Fig. 3, Garofalo et al., Appendix). Confirming the results of other investigators (18, 20), we found that the highest proliferation rates were induced with 100 ng/ml leptin, while lower leptin concentrations (1 and 10 ng/ml) were less mitogenic.

At days 1 and 3, 100 ng/ml leptin increased cell growth over that seen in SFM by 20 and 38%, respectively (Fig. 3). Leptin did not affect cell proliferation in the presence of 17-beta-estradiol (E2) at any time point. However, leptin consistently counteracted cytostatic effects of ICI. Specifically, at day 1 and 3 the addition of leptin to ICI-treated cells increased proliferation by ~30 and ~45 %, respectively (Fig. 3). ICI was used at a concentration of 10 nM, which is cytostatic but not cytotoxic for MCF-7 cells, as demonstrated by us before (48).

### **4. Effects of leptin on the nuclear abundance of ERα in ICI-treated MCF-7 cells.**

To study the mechanism of leptin interference with ICI, we assessed the abundance of cytoplasmic and nuclear ERα in MCF-7 cells treated with E2, E2 + ICI, ICI, ICI + leptin, and leptin alone (Fig. 4, Garofalo et al., Appendix). As expected, E2 significantly (by ~ 50%) decreased the cytoplasmic expression of ERα and increased (by ~150 %) its nuclear levels, relative to ERα under SFM conditions. Also predictably, ICI treatment induced the degradation of ERα, resulting in reduced ERα abundance in the cytoplasm and nucleus (~ 85 and 70%, respectively). These effects of ICI were partially reversed in the presence of E2 (Fig. 4). The addition of leptin to ICI-treated cells significantly improved nuclear ERα expression, but had only minimal effects on the cytoplasmic ERα levels. Leptin alone had no significant effects on ERα expression in the cytoplasmic and nuclear compartments (Fig. 4).

The above observations were confirmed by fluorescence microscopy of ERα in MCF-7 cells treated with ICI in the presence or absence of leptin. ERα accumulated in the nucleus upon E2 stimulation, while a 24 h-treatment with ICI dramatically reduced nuclear ERα expression. The effect of ICI was prevented by the addition of leptin (Fig. 4B).

### **5. Leptin increases ERα recruitment to the pS2 promoter in ICI-treated MCF-7 cells.**

The function of nuclear ERα under different conditions was addressed with ChIP assay (Fig. 5, Garofalo et al., Appendix). We found that the stimulation of MCF-7 cells with E2 increased (~ 5-fold) the recruitment of ERα to the classical E2-responsive ERE-containing pS2 gene promoter. This effect coincided with the greater

association of pol II to the pS2 regulatory sequences (Fig. 5). In the presence of ICI, the recruitment of ERa to the pS2 promoter was similar to that seen in untreated cells, and the recruitment of pol II was completely blocked. The addition of leptin counteracted the inhibitory action of ICI, resulting in a greater association of pol II (increased by ~ 2-fold) and ERa (~ 3-fold) to the pS2 promoter. Leptin alone did not stimulate the recruitment of either ERa or pol II to the pS2 promoter (Fig. 5).

#### **6. Effects of leptin on ERa transcriptional activity in ICI-treated MCF-7 cells.**

We validated ChIP results using ERE-luciferase reporter system (Fig. 6, Garofalo et al., Appendix). In control experiments, E2 significantly (by ~ 250%) stimulated ERE-dependent transcription above the basal level (SFM), while the addition of ICI to E2 abolished this effect. Leptin alone did not activate ERE transcription above that seen under SFM conditions. Similarly, leptin did not improve E2-dependent ERE activation. In the presence of ICI, ERE activity decreased ~ 60% below basal levels. In contrast, in ICI + leptin co-treated cells, ERE activity was increased ~ 50 % above the level recorded in untreated cells.

#### **7. Leptin increases ERa half-life and reduces ERa ubiquitination in ICI-treated MCF-7 cells.**

ICI is known to induce rapid degradation of ERa in MCF-7 (46, 50). We asked whether leptin increases ERa stability in ICI-treated cells (Fig. 7, Garofalo et al., Appendix). Using pulse-chase assay, we confirmed previous observations that ERa half-life in untreated cells is ~ 4h, and in ICI-treated cells ~ 1.5 h (47, 50). The addition of leptin increased ERa half-life to ~2.5 h (Fig. 7A).

Next, we addressed the mechanism by which leptin might decrease ERa turnover. Since ICI- and E2-dependent degradation of ERa occurs through the ubiquitin-proteasome pathway (46, 47), we studied the effects of leptin on ERa ubiquitination (Fig. 7B). The ubiquitination of ERa was undetectable in untreated cells, while it was increased when the cells were treated for 1 h with ICI or E2. The addition of leptin greatly reduced ERa ubiquitination in ICI-treated cells (Fig. 7B). Leptin alone did not induce ERa ubiquitination. However, ERa ubiquitination was still observed when ICI was challenged with E2 (data not shown). The above treatments had no effects on the expression and ubiquitination of  $\beta$ -catenin, a known target of proteasome (49)(Fig. 7B).

**Key Research Accomplishments:**

- Documented that ERa-positive breast cancer cell lines express signaling form of leptin receptors ObRl ;
- Demonstrated that leptin is a mitogen for MCF-7 ERa-positive breast cancer cells;
- Demonstrated that in MCF-7 cells leptin stimulates several growth and anti-apoptotic signaling pathways, including Akt/GSK3, ERK1/2 and STAT3;
- Demonstrated that in MCF-7 cells leptin interferes with the action of the antiestrogen ICI182,780;
- Demonstrated that leptin-mediated interference with ICI182,780 is related to increased ERa stability and improved ERa transcriptional activity.

**Reportable Outcomes:**

**1. Manuscripts and scientific presentations:**

**Manuscripts:**

Garofalo, C., Sisci, D., Surmacz, E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin. Cancer Res., in press, 2004.

Garofalo, C., Koda, M., Sulkowski, S., Surmacz, E. Expression of leptin and leptin receptors in primary and metastatic breast cancer. In preparation.

**Abstracts:**

Garofalo, C., Sisci, D., Morelli, C., Surmacz, E. Leptin (obesity protein) interferes with the action of antiestrogen ICI 182,780 in MCF-7 breast cancer cells. IV International Symposium on Nutrition and Cancer. Washington DC, July 16-18, 2004

Garofalo, C., Sisci, D., Morelli, C., Surmacz, E. Leptin (obesity protein) interferes with the action of antiestrogen ICI 182,780 in MCF-7 breast cancer cells. IV International Symposium on Hormonal Carcinogenesis, Valencia, Spain, July 22-25, 2003.

**2. Patents and licenses: None**

**3. Degrees: N/A**

**4. Development of biologic reagents: None**

**5. Databases: None**

**6. Funding applied for: None**

**7. Employment applied for: None**



## Conclusions

Leptin (obesity protein) may play a role in breast cancer development by stimulating the growth of breast cancer cells. In addition, leptin seems to counteract the action of antiestrogens, thus it may be involved in the development of antiestrogen resistance. Further studies are planned to probe the molecular mechanism of this effect and the relevance of these findings in clinical setting.

## References

1. Stephenson GD, Rose DP. Breast cancer and obesity: an update. *Nutr Cancer*. 2003; 45: 1-16.
2. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). *Int J Oncol*. 2002; 21: 1285-92.
3. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. *Proc Soc Exp Biol Med*. 1997; 216: 28-43.
4. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *J Clin Oncol*. 2002; 20: 1128-43.
5. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. *Ann Intern Med*. 1994; 120: 18-25.
6. Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D. Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. *Proc Soc Exp Biol Med*. 1991; 196: 381-4.
7. Waxler SH. Obesity and cancer susceptibility in mice. *Am J Clin Nutr*. 1960; 8: 760-6.
8. Wolff GL, Kodell RL, Cameron AM, Medina D. Accelerated appearance of chemically induced mammary carcinomas in obese yellow (A<sup>vy</sup>/A) (BALB/c X VY) F1 hybrid mice. *J Toxicol Environ Health*. 1982; 10: 131-42.
9. Heston WE, Vlahakis G. Genetic obesity and neoplasia. *J Natl Cancer Inst*. 1962; 29: 197-209.
10. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. *Eur J Endocrinol*. 2000; 143: 293-311.
11. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. *J Mammary Gland Biol Neoplasia*. 2002; 7: 49-66.
12. Bonnet M, Delavaud C, Laud K, Gourdou I, Leroux C, Djiane J, et al. Mammary leptin synthesis, milk leptin and their putative physiological roles. *Reprod Nutr Dev*. 2002; 42: 399-413.
13. Brann DW, Wade MF, Dhandapani KM, Mahesh VB, Buchanan CD. Leptin and reproduction. *Steroids*. 2002; 67: 95-104.
14. Goumenou AG, Matalliotakis IM, Koumantakis GE, Panidis DK. The role of leptin in fertility. *Eur J Obstet Gynecol Reprod Biol*. 2003; 106: 118-24.
15. Sierra-Honigmann MR, Nat AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. *Science*. 1998; 281:1683-6.

16. Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. *FASEB J.* 2000; 14: 2329-33.
17. Tsuchiya T, Shimizu H, Horie T, Mori M. Expression of leptin receptor in lung: leptin as a growth factor. *Eur J Pharmacol.* 1999; 365: 273-9.
18. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. *J Natl Cancer Inst.* 2002; 94:1704-11.
19. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. *Biochem Biophys Res Commun.* 2002; 293: 622-8.
20. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. *Mol. Cell. Endocrinol.* 2002; 188:219-26.
21. Baratta M, Grolli S, Tamanini C. Effect of leptin in proliferating and differentiated HC11 mouse mammary cells. *Regul Pept.* 2003; 113:101-7.
22. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali M, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. *Biochim Biophys Acta.* 2002; 1592:107-16.
23. Tartaglia LA. The leptin receptor. *J Biol Chem.* 1997; 272: 6093-6.
24. Barr VA, Lane K, Taylor SI. Subcellular localization and internalization of the four human leptin receptor isoforms. *J Biol Chem.* 1999; 274: 21416-24.
25. Sweeney G. Leptin signalling. *Cell Signal.* 2002; 14: 655-63.
26. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. *FEBS Lett.* 2003; 546: 45-50.
27. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. *J Biol Chem.* 1997; 272: 32686-95.
28. Bjorbaek C, Buchholz RM, Davis SM, Bates SH, Pierroz DD, Gu H, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. *J Biol Chem.* 2001; 276: 4747-55.
29. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG, Funanage VL. Leptin expression in human mammary epithelial cells and breast milk. *J Clin Endocrinol Metab.* 1998; 83: 1810-3.
30. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, et al. Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. *Breast Cancer Res Treat.* 2003; 77: 205-15.
31. O'brien SN, Welter BH, Price TM. Presence of leptin in breast cell lines and breast tumors. *Biochem Biophys Res Commun.* 1999; 259: 695-8.
32. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, et al. Leptin expression in colorectal and breast cancer patients. *Int J Mol Med.* 2000; 5: 421-6.
33. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). *Cancer Causes Control.* 2000; 11: 383-8.

34. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. *Int J Cancer*. 1999; 80: 523-6.
35. Simpson ER. Sources of estrogen and their importance. *J Steroid Biochem Mol Biol*. 2003; 86: 225-30.
36. Magoffin DA, Weitsman SR, Aagarwal SK, Jakimiuk AJ. Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. *Ginekol Pol*. 1999; 70: 1-7.
37. Kitawaki J, Kusuki I, Koshiba H, Tsukamoto K, Honjo H. Leptin directly stimulates aromatase activity in human luteinized granulosa cells. *Mol Hum Reprod*. 1999; 5: 708-13.
38. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. *J Biol Chem*. 2003; 278: 28668-76.
39. Spicer LJ, Francisco CC. The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. *Endocrinology*. 1997; 138: 3374-9.
40. Ghizzoni L, Barreca A, Mastorakos G, Furlini M, Vottero A, Ferrari B, et al. Leptin inhibits steroid biosynthesis by human granulosa-lutein cells. *Horm Metab Res*. 2001; 33: 323-8.
41. Machinal-Quelin F, Dieudonne MN, Pecquery R, Leneuve MC, Giudicelli Y. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. *Endocrine*. 2002; 18: 179-84.
42. Bennett PA, Lindell K, Karlsson C, Robinson IC, Carlsson LM, Carlsson B. Differential expression and regulation of leptin receptor isoforms in the rat brain: effects of fasting and oestrogen. *Neuroendocrinology*. 1998; 67: 29-36.
43. Lindell K, Bennett PA, Itoh Y, Robinson IC, Carlsson LM, Carlsson B. Leptin receptor 5'untranslated regions in the rat: relative abundance, genomic organization and relation to putative response elements. *Mol Cell Endocrinol*. 2001; 172: 37-45.
44. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. *Expert Rev Anticancer Ther*. 2002; 2: 151-60.
45. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. *Cancer*. 2000; 89: 817-25.
46. Marsaud V, Gougelet A, Maillard S, Renoir JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. *Mol Endocrinol*. 2003; 17: 2013-27.
47. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. *Mol Endocrinol*. 2003; 17: 356-65.
48. Salerno M., Sisci D, Mauro L, Guvakova M, Ando S, Surmacz E. Insulin receptor substrate 1 (IRS-1) is a target of a pure antiestrogen ICI 182,780 in breast cancer cells. *Int J Cancer*. 1999; 81: 299-304.

49. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. *Cancer Biol Ther.* 2002; 1: 337-41.
50. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. *Proc Natl Acad Sci U S A.* 1992; 89:4037-41.

# Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells

Cecilia Garofalo,<sup>1</sup> Diego Sisci,<sup>2</sup> and Eva Surmacz<sup>1</sup>

<sup>1</sup>Kimmel Cancer Center, Thomas Jefferson University, Philadelphia Pennsylvania; and <sup>2</sup>Faculty of Pharmacy, University of Calabria, Cosenza, Italy

## ABSTRACT

**Purpose:** Obesity is a risk factor for breast cancer development in postmenopausal women and correlates with shorter disease-free and overall survival in breast cancer patients, regardless of menopausal status. Adipose tissue is a major source of leptin, a cytokine regulating energy balance and controlling different processes in peripheral tissues, including breast cancer cell growth. Here, we investigated whether leptin can counteract antitumorigenic activities of the antiestrogen ICI 182,780 in breast cancer cells.

**Experimental Design:** Mitogenic response to leptin and the effects of leptin on ICI 182,780-dependent growth inhibition were studied in MCF-7 estrogen receptor  $\alpha$ -positive breast cancer cells. The expression of leptin receptor and the activation of signaling pathways were studied by Western immunoblotting. The interference of leptin with ICI 182,780-induced estrogen receptor  $\alpha$  degradation was probed by Western immunoblotting, fluorescence microscopy, and pulse-chase experiments. Leptin effects on estrogen receptor  $\alpha$ -dependent transcription in the presence and absence of ICI 182,780 were studied by luciferase reporter assays and chromatin immunoprecipitation.

**Results:** MCF-7 cells were found to express the leptin receptor and respond to leptin with cell growth and activation the signal transducers and activators of transcription 3, extracellular signal-regulated kinase-1/2, and Akt/GSK3/ $\beta$  pathways. The exposure of cells to 10 nmol/L ICI 182,780 blocked cell proliferation, induced rapid estrogen receptor  $\alpha$  degradation, inhibited nuclear estrogen receptor  $\alpha$  expression, and reduced estrogen receptor  $\alpha$ -dependent transcription from estrogen response element-containing promoters. All of these effects of ICI 182,780 were signifi-

cantly attenuated by simultaneous treatment of cells with 100 ng/mL leptin.

**Conclusions:** Leptin interferes with the effects of ICI 182,780 on estrogen receptor  $\alpha$  in breast cancer cells. Thus, high leptin levels in obese breast cancer patients might contribute to the development of antiestrogen resistance.

## INTRODUCTION

Numerous epidemiologic studies documented that obesity is a risk factor for postmenopausal breast cancer (1–4). Furthermore, increased body weight and body mass index have been associated with shorter disease-free and overall survival in breast cancer patients, regardless of age and menopausal status (4). Some studies also suggested that obesity can reduce the efficacy of anti-breast cancer chemotherapy (5). In animal models, high adiposity has been linked with increased incidence of spontaneous and chemically induced mammary tumors (6–9).

Human obesity is associated with increased levels of leptin, a  $M_r$  16,000 circulating hormone controlling food intake and energy balance by providing signals to the hypothalamus (10). In addition to its central nervous system activities, leptin regulates multiple processes in peripheral tissues, including hematopoiesis, immune responses, puberty, pregnancy, and lactation (10–14). In cellular models, leptin has been shown to activate proliferation, angiogenesis, motility, and invasion (10, 15–22). The major source of leptin is adipose tissue; however, leptin can be produced by other organs, including the mammary gland (10–12).

The activities of leptin are mediated through the transmembrane leptin receptor (ObR; ref. 23). In human tissues, at least four isoforms of ObR with different COOH-terminal cytoplasmic domains have been described previously (24). The full (long) form of ObR (ObR<sub>L</sub>) is 1165 amino acids long ( $M_r$  ~150,000–190,000) and contains extracellular, transmembrane, and intracellular domains. The extracellular domain binds ligand, whereas intracellular tail recruits and activates signaling substrates. Only ObR<sub>L</sub> has a full signaling potential, whereas the shorter ObR isoforms have diminished or abolished signaling capability (25–28). The signaling pathways known to be activated by ObR<sub>L</sub> include the classic cytokine JAK2/signal transducers and activators of transcription 3 (STAT3) pathway; the Ras/extracellular signal-regulated kinase (ERK) signaling cascade; the kinases phosphatidylinositol 3'-kinase, Akt, p38, and protein kinase C; nitric oxide; and phospholipase C $\gamma$  (25–27). Ultimately, induction of ObR<sub>L</sub> can activate the expression of several genes involved in cell proliferation, including *c-fos*, *c-jun*, *junB*, *egr-1*, and *socs3* (25, 26).

Although leptin is necessary for normal mammary gland development in rodents and humans (11, 12, 18, 29), recent studies suggested that the hormone might be involved in mammary carcinogenesis (18–22, 30, 31). Notably, leptin (31) and ObR (20) have been detected in human breast cancer specimens.

Received 2/2/04; revised 6/4/04; accepted 6/22/04.

**Grant support:** Department of Defense Breast Cancer Program grants DAMD17-01-1-0651 (E. Surmacz) and DAMD17-03-1-0655 (E. Surmacz) and Cancer Research Foundation of America (C. Garofalo and E. Surmacz).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Eva Surmacz, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 631, Philadelphia, PA 19107. Phone: 215-503-4512; Fax: 215-923-0249; E-mail: eva.surmacz@jefferson.edu.

©2004 American Association for Cancer Research.

AQ: N

AQ: A O.K.

In breast cancer cell lines T47D and MCF-7, leptin has been shown to stimulate DNA synthesis and cell growth acting through the STAT3 and ERK1/2 signaling pathways (18–20, 22). Leptin has also been shown to induce transformation (anchorage-independent growth) of cancer but not normal breast epithelial cells (18). Finally, leptin-deficient mice have decreased incidence of spontaneous and oncogene-induced mammary tumors (30).

The possible impact of leptin produced in mammary tissue on breast cancer development is yet unknown. The role of circulating leptin remains unclear, with clinical studies reporting positive (32), negative (33), or no association (34) of serum leptin levels with breast cancer.

In addition to leptin, adipose tissue is a source of estrogens produced, via aromatase conversion, from androstenedione in postmenopausal women (35). Recent studies suggest that leptin and estrogen systems are involved in functional cross-talk. For instance, leptin has been shown to modulate, either positively (36–38) or negatively (39, 40), aromatase activity. Reciprocally, 17- $\beta$ -estradiol ( $E_2$ ) has been found to up-regulate leptin mRNA and protein synthesis in adipocytes (41).  $E_2$  can also modulate ObR expression (42), possibly through the putative estrogen-responsive element in the *ObR* gene promoter (43).

In this study, we explored a new aspect of leptin/estrogen cross-talk. Specifically, we asked whether leptin can interfere with antitumorigenic effects of the antiestrogen ICI 182,780. ICI 182,780 [Faslodex (fulvestrant); AstraZeneca], which induces estrogen receptor  $\alpha$  degradation through ubiquitin-mediated mechanism (44–47), is currently used for treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following other hormonal therapy (44).

## MATERIALS AND METHODS

**Cell Lines and Cell Culture.** MCF-7, T47D, MDA-MB-231, and MDA-MB-435 cells were obtained from American Type Culture Collection (Manassas, VA). The cells were grown in Dulbecco's modified Eagle's medium:Ham's F-12 containing 5% calf serum. In the experiments requiring  $E_2$ - and serum-free conditions, the cells were cultured in phenol red-free serum-free medium (48, 49).

**Cell Growth.** MCF-7 cells were plated in 35-mm plates at a concentration of  $1.5$  to  $2.0 \times 10^5$  cells/plate in Dulbecco's modified Eagle's medium:Ham's F-12 (1:1) containing 5% calf serum. The following day (day 0), the cells at approximately 70% confluence were shifted to serum-free medium and treated with 10 nmol/L  $E_2$  (Sigma, St. Louis, MO), 10 nmol/L ICI 182,780 (Tocris Cookson), 100 ng/mL leptin (R&D Systems), or 10 nmol/L ICI 182,780 + 100 ng/mL leptin, singly or in combination. Cell number was determined by direct cell counting at days 0, 1, and 3. The number of cells at day 0 was taken as 100%, and the relative values at days 1 and 3 were calculated for each treatment.

**Fluorescence Microscopy.** Fifty percent confluent MCF-7 cells grown on coverslips were fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100, washed three times with PBS, and incubated for 1 hour with 2  $\mu$ g/mL estrogen receptor  $\alpha$  Ab H-184 (Santa Cruz Biotechnology, Santa Cruz, CA). Next,

the cells were washed three times with PBS, and incubated with the rhodamine-conjugated goat antirabbit immunoglobulin G (Calbiochem) used as a secondary Ab. After this step, the slides were covered with Vectashield containing 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) to allow visualization of cellular nuclei. Nuclear abundance of estrogen receptor  $\alpha$  under different conditions was assessed using Zeiss Axiovert zoom microscope with magnification  $\times 100$ .

**Immunoprecipitation and Western Blotting.** The expression of ObR, activation of leptin signaling pathways, and the abundance of estrogen receptor  $\alpha$  were assessed by Western blotting or immunoprecipitation followed by Western blotting using total protein lysates or fractionated proteins, where appropriate. Total cell proteins were obtained using RIPA buffer containing 1% Nonidet P40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS. Cytoplasmic proteins were obtained using the lysis buffer containing 50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 1% Triton X-100, 1.5 mmol/L  $MgCl_2$ , EGTA, 10 mmol/L (pH 7.5), glycerol 10%, and inhibitors (0.1 mmol/L  $Na_3VO_4$ , 1% phenylmethylsulfonyl fluoride, and 20 mg/mL aprotinin). After the collection of cytoplasmic proteins, the nuclei were lysed with the nuclear buffer containing 20 mmol/L HEPES (pH 8), 0.1 mmol/L EDTA, 5 mmol/L  $MgCl_2$ , 0.5 mol/L NaCl, 20% glycerol, 1% Nonidet P40, and inhibitors (as above). For Western blotting, 50 mg of protein lysates were separated on a 4 to 15% polyacrylamide denaturing gel (PAGE), and proteins of interest were detected with specific antibodies (Abs) and visualized by ECL chemiluminescence (Amersham Biosciences). The intensity of bands representing relevant proteins was measured by Scion Image laser densitometry scanning program.

For immunoprecipitations, 500  $\mu$ g of protein lysates were incubated with primary Abs at 4°C or 18 hours in HNTG buffer [20 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 0.1% Triton X-100, 10% glycerol, and 0.1 mmol/L  $Na_3VO_4$ ], and then the antigen/Ab complexes were precipitated with Protein A agarose (Calbiochem) for pAbs or Protein G for mAbs (Calbiochem) at for 2 hours in HNTG buffer. In control samples, primary immunoprecipitating Abs were replaced with normal rabbit immunoglobulin G (Santa Cruz Biotechnology). The immunoprecipitated proteins were washed three times with HNTG buffer, separated on PAGE, and processed by Western blotting.

**Antibodies for Western Blotting and Immunoprecipitation.** ObR expression was studied by Western blotting with the anti-ObR H300 pAb (Santa Cruz Biotechnology). Estrogen receptor  $\alpha$  was assessed by Western blotting with the anti-estrogen receptor  $\alpha$  F-10 mAb (Santa Cruz Biotechnology). Ubiquitination of estrogen receptor  $\alpha$  was assessed by immunoprecipitation/Western blotting in 500  $\mu$ g of total proteins. In this assay, estrogen receptor  $\alpha$  was immunoprecipitated with the anti-estrogen receptor  $\alpha$  F10 mAb, and ubiquitination was detected by Western blotting with the anti-ubiquitin P4D1 mAb (Santa Cruz Biotechnology). The expression of STAT3 was probed in 500  $\mu$ g of total proteins by immunoprecipitation and Western blotting with the anti-STAT 3 pAb (Santa Cruz Biotechnology). The activation of STAT 3 was measured in STAT3 immunoprecipitations with the anti-STAT3 Ser<sup>727</sup> pAb (UBI, Lake Placid, NY) and the anti-STAT Tyr<sup>705</sup> pAb (Cell Signaling). The following Abs were used to study other elements of

AQ: E  
San Diego,  
CA

AQ: F  
Piscataway  
NJ

Beverly,  
MA  
AQ: G

AQ: B

Accdes-  
field,  
United  
Kingdom

Ellisville,  
MI  
AQ: C  
AQ: D

Minneapolis,  
MN

leptin signaling by Western blotting: anti-phospho-ERK1/2 Thr<sup>202</sup>/Tyr<sup>204</sup> mAb (Cell Signaling); anti-p44/42 MAP kinase pAb (Cell Signaling); anti-phospho-Akt Ser<sup>473</sup> pAb (Cell Signaling); anti-Akt pAb (Cell Signaling); anti-phospho-GSK3 $\beta$  pAb (Cell Signaling); and anti-phospho-pRB pAb (Cell Signaling). The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and nucleolin was assessed by Western blotting as controls of loading and purity of lysates with the anti-GAPDH mAb (Research Diagnostics Inc.) and the anti-nucleolin C23 mAb (Santa Cruz Biotechnology), respectively. The expression of  $\beta$ -catenin was probed with the anti- $\beta$ -catenin mAb (BD Transduction Laboratories). All Abs were used at concentrations recommended by the manufacturers.

**Estrogen Response Element Reporter Assays.** MCF-7 cells were grown in 24-well plates. At 70% confluence, the cultures were transfected for 6 hours with 0.5  $\mu$ g DNA/well using Fugene 6 (DNA:Fugene 3:1; Roche, Gif-Oberfrick, Switzerland). All transfection mixtures contained 0.5  $\mu$ g of the reporter plasmid, estrogen response element-Luc, encoding the firefly luciferase (Luc) cDNA under the control of the TK promoter and three estrogen response element sequences. In addition, to test transfection efficiency, each DNA mixture contained 50 ng of pRL-TKLuc, a plasmid encoding renilla luciferase (RI Luc; Promega, Madison, WI). Upon transfection, the cells were shifted to serum-free medium for 16 hours and then treated with 10 nmol/L E<sub>2</sub>, 10 nmol/L ICI 182,780, 100 ng/mL leptin, and ICI 182,780 + leptin for 24 hours. Untreated cells in serum-free medium served as controls. Luciferase activity (Luc and RI Luc) in cell lysates was measured using Dual Luciferase Assay System (Promega) following the manufacturer's instructions. The values obtained for Luc were normalized to that of RI Luc to generate relative Luc units.

**Chromatin Immunoprecipitation.** We followed the chromatin immunoprecipitation methodology described by Shang *et al.* (50) with minor modifications. MCF-7 were grown in 100-mm plates. Ninety percent confluent cultures were shifted to serum-free medium for 24 hours and then treated for 4 hours with 10 nmol/L E<sub>2</sub>, 10 nmol/L ICI 182,780, 100 ng/mL leptin, 10 nmol/L E<sub>2</sub> + 10 nmol/L ICI 182,780, or 100 ng/mL leptin + 10 nmol/L ICI 182,780, or left untreated in serum-free medium. After treatment, the cells were washed twice with PBS and cross-linked with 1% formaldehyde at 37°C for 10 minutes. Next, the cells were washed twice with PBS at 4°C, collected, and resuspended in 200 mL of lysis buffer [1% SDS, 10 mmol/L EDTA, and 50 mmol/L Tris-Cl (pH 8.1)] and left on ice for 10 minutes. Then, the cells were sonicated four times for 10 seconds at 40% maximal power (Fisher Sonic Dismembrator), and insoluble material was collected by centrifugation at 4°C for 10 minutes at 14,000 rpm. Supernatants were diluted in 1.3 mL of IP buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mmol/L EDTA, 16.7 mmol/L Tris-Cl (pH 8.1), and 16.7 mmol/L NaCl] and precleared with 80 mL of sonicated salmon sperm DNA/protein A agarose (UBI) for 1 hour at 4°C. The precleared chromatin was immunoprecipitated with either the anti-estrogen receptor  $\alpha$  mAb F-10 (Santa Cruz Biotechnology) or the anti-polymerase II CTD4H8 mAb (UBI) for 12 hours. After that, 60 mL of salmon sperm DNA/protein A agarose were added, and precipitation continued for 4 hours at 4°C. After pelleting, the precipitates were washed sequentially for 5 minutes with the following

buffers: wash A [0.1% SDS, 1% Triton X-100, 2 mmol/L EDTA, 20 mmol/L Tris-Cl (pH 8.1), and 150 mmol/L NaCl], wash B [0.1% SDS, 1% Triton X-100, 2 mmol/L EDTA, 20 mmol/L Tris-Cl (pH 8.1), and 500 mmol/L NaCl], and wash C [0.25 mol/L LiCl, 1% Nonidet P40, 1% sodium deoxycholate, 1 mmol/L EDTA, and 10 mmol/L Tris-Cl (pH 8.1)]. The precipitates were then washed twice with 10 mmol/L Tris and 1 mmol/L EDTA. The immune complexes were eluted with the buffer containing 1% SDS and 0.1 mol/L NaHCO<sub>3</sub>. The eluates were reverse cross-linked by heating at 65°C for 12 hours and digested with 0.5 mg/mL proteinase K at 45°C for 1 hour. DNA was obtained by phenol and phenol/chloroform extractions. Two mL of 10 mg/mL yeast tRNA were added to each sample, and DNA was precipitated with ethanol for 12 hours at 4°C and resuspended in 20 mL of 10 mmol/L Tris and 1 mmol/L EDTA. Four mL of each sample were used for PCR with pS2 promoter sequences containing estrogen response element: upstream, 5'-TGG CCA GGC TAG TCT CAA AC-3'; and downstream, 5'-CTT AAT CCA GGT CCT ACT CAT A-3'. The PCR conditions were: 30 seconds at 94°C, 50 seconds at 60°C, and 2 minutes at 72°C. The amplification products obtained in 35 cycles were analyzed in a 2% agarose gel and visualized by ethidium bromide staining. The intensity of bands was measured by laser scanning.

**Pulse-Chase Labeling.** Seventy percent of cultures were shifted to methionine- and cysteine-free Dulbecco's modified Eagle's medium (Life Technologies) for 16 hours and then metabolically labeled with 100 mCi/mL <sup>35</sup>S (Express protein labeling mix; Perkin-Elmer, Fremont, CA) for 1 hour. After that, the labeling medium was replaced with serum-free medium containing 10 nmol/L ICI 182,780 or 10 nmol/L ICI 182,780 + 100 ng/mL leptin, and the cultures were grown for 1, 2, 4, 6, and 8 hours. Untreated cells in serum-free medium served as controls. At specific time points, the cells were lysed in RIPA buffer, and 500 mg of proteins were precipitated with the anti-estrogen receptor  $\alpha$  F10 mAb. The estrogen receptor  $\alpha$  immunoprecipitations were separated by SDS-PAGE, and labeled estrogen receptor  $\alpha$  was identified by autoradiography.

**Statistical Analysis.** Data were analyzed with Student's *t* test, where appropriate. Means  $\pm$  SE are shown.

## RESULTS

**ObR<sub>1</sub> Is Expressed in Estrogen Receptor  $\alpha$ -Positive Breast Cancer Cell Lines.** To study possible effects of leptin on ICI 182,780 action, we first assessed the expression of ObR<sub>1</sub>, a signaling form of ObR, in different breast cancer cell lines. Several ObR isoforms (*M<sub>r</sub>* ~190,000–150,000) were detected in estrogen receptor  $\alpha$ -positive and estrogen receptor  $\alpha$ -negative breast cancer cells by Western blotting (Fig. 1). Notably, the greatest expression of ObR<sub>1</sub> *M<sub>r</sub>* 190,000 was found in estrogen receptor  $\alpha$ -positive cell lines, MCF-7 and T47D. The shorter isoforms of ObR were abundant in estrogen receptor  $\alpha$ -negative cells (Fig. 1). For additional experiments, we selected MCF-7 cells because they are E<sub>2</sub>- and ICI 182,780-responsive and express high levels of ObR<sub>1</sub>.

**Leptin Induces Multiple Signaling Pathways in MCF-7 Cells.** We examined leptin effects on the activation of different ObR<sub>1</sub> signaling pathways in MCF-7 cells. In addition to

AQ: L  
Gaithers-  
burg, ME

F1

Flanders,  
NJ

AQ: H

AQ: I


San Jose,  
CA

Pittsburgh,  
PA

AQ: J

AQ: K

immuno-  
precipita-  
tion



**Fig. 1** ObR is expressed in breast cancer cell lines. **Left panel.** The expression of ObR was determined by Western blotting in 50  $\mu$ g of cytoplasmic protein lysates obtained from proliferating estrogen receptor  $\alpha$ -positive (MCF-7 and T47D) and estrogen receptor  $\alpha$ -negative (MDA-MB-231 and MDA-MB-435) cells. The ObR Ab used for Western blotting recognizes a common domain in ObR, revealing several isoforms of ObR ( $M_r$  150,000–190,000) indicated by arrows. The  $M_r$  190,000 isoform represents ObR $_1$ , which is highly expressed in MCF-7 and T47D cells. **Right panel.** The specificity of the ObR Ab was tested using 250 ng of a  $M_r$  60,000 ObR-tagged fusion protein (amino acids 541–840 of human ObR) provided as a positive control by the manufacturer of ObR Abs (Santa Cruz Biotechnology). The molecular weight markers are indicated on the left of both panels.

ObR $_1$  pathways known to be induced in breast cancer cells, i.e., STAT3 and ERK1/2 (18–20), we studied whether leptin can activate Akt/GSK3 antiapoptotic signaling and whether it can phosphorylate (and thereby block) a key cell cycle inhibitor, pRb.


The stimulation of ObR $_1$  by leptin was assessed at different time points, from 5 minutes to 24 hours. We used leptin at a concentration of 100 ng/mL, which in our preliminary dose-response experiments proved to exert maximal mitogenic effects (data not shown). The stimulation of MCF-7 cells with leptin induced multiple signaling elements, including STAT3, ERK1/2, Akt, and GSK3 $\beta$  (Fig. 2). The phosphorylation of STAT3 on Tyr<sup>705</sup> and on Ser<sup>727</sup>, reflecting STAT3 activation, was maximal at 5 minutes of leptin treatment and then declined to basal levels (Fig. 2A). The stimulation of ERK1/2 became detectable at 15 minutes, was maximal at 1 hour, and persisted up to 24 hours. The activation of Akt appeared at 15 minutes, was maximal at 1 hour, and was reduced to basal levels at 4 hours. GSK3 $\beta$ , a downstream effector of Akt and other kinases was induced at 5 minutes, reached the maximal activation at 1 hour, and then declined to basal levels at 24 hours (Fig. 2B). These leptin effects coincided with the phosphorylation of pRb on Ser<sup>795</sup> (maximum at 1–4 hours; Fig. 2B).

**Leptin Stimulates the Proliferation of MCF-7 Cells and Interferes with ICI 182,780-Dependent Growth Inhibition.** The mitogenic effects of leptin at doses 1 to 1000 ng/mL were studied in MCF-7 cells at 1 and 3 days of treatment. Confirming the results of other investigators (18, 20), we found that the highest proliferation rates were induced with 100 ng/mL leptin, whereas lower leptin concentrations (1 and 10 ng/mL) were less mitogenic (data not shown). Increasing the dose over 100 ng/mL did not improve growth response (data not shown).

At days 1 and 3, 100 ng/mL leptin increased cell growth over that seen in serum-free medium by 20 and 38%, respectively (Fig. 3). Leptin did not affect cell proliferation in the


presence of E<sub>2</sub> at any time point. However, leptin consistently counteracted cytostatic effects of ICI 182,780. Specifically, at day 1 and 3, the addition of leptin to ICI 182,780-treated cells increased proliferation by ~30 and ~45%, respectively (Fig. 3). In these studies, ICI 182,780 was used at a concentration of 10 nmol/L, which is cytostatic but not cytotoxic for MCF-7 cells, as demonstrated by us previously (48).

**Effects of Leptin on the Nuclear Abundance of Estrogen Receptor  $\alpha$  in ICI 182,780-Treated MCF-7 Cells.** To study the mechanism of leptin interference with ICI 182,780, we assessed the abundance of cytoplasmic and nuclear estrogen receptor  $\alpha$  in MCF-7 cells treated with E<sub>2</sub>, E<sub>2</sub> + ICI 182,780,



**Fig. 2** Leptin activates multiple signaling pathways in MCF-7 cells. **A,** activation of STAT3. MCF-7 cells were synchronized in serum-free medium for 16 hours and then stimulated with 100 ng/mL leptin (LPT) for 5 and 10 minutes or left untreated in serum-free medium. STAT3 was immunoprecipitated (IP) with the anti-STAT3 pAb (Santa Cruz Biotechnology) from 500  $\mu$ g of total protein lysates, and the activation of STAT3 was visualized with the STAT3 Ser<sup>727</sup> pAb (STAT3/S727; UBI) and then after stripping of the membrane with the anti-STAT3 Tyr<sup>705</sup> pAb (STAT3/Y705; Cell Signaling). In control experiments, the proteins were precipitated with control rabbit immunoglobulin G and processed for Western blotting (WB), as described above. **B,** activation of ERK1/2, Akt, GSK3, and Rb. MCF-7 cells were synchronized in serum-free medium for 16 hours and then stimulated with 100 ng/mL leptin (LPT) for 5 minutes to 24 hours or left untreated in serum-free medium. The activation (phospho) and levels of ERK1/2, Akt, GSK3 $\beta$ , and pRb were assessed by Western blotting in 50  $\mu$ g of proteins using specific Abs.





**Fig. 3** Leptin stimulates the growth of MCF-7 cells and counteracts the effects of ICI 182,780. Seventy percent confluent MCF-7 cells were synchronized in serum-free medium for 16 hours and treated with 100 ng/mL leptin (LPT), 10 nmol/L ICI 182,780 (ICI), leptin + ICI 182,780 (LPT+ICI), 10 nmol/L E<sub>2</sub>, or E<sub>2</sub> + ICI 182,780 (E<sub>2</sub>+ICI) for 1 and 3 days or were left untreated (SFM). Cell number was determined by direct cell counting. Please note that MCF-7 cells grow in serum-free medium due to activation of autocrine pathways, as described by us previously (57, 58). Cell number at day 0 in serum-free medium was taken as 100%. The experiments were performed at least four times. The bars demonstrate relative cell number ( $\pm$ SEM) at different time points. The differences between serum-free medium and leptin values were statistically significant at days 1 and 3 ( $P < 0.05$ ).

ICI 182,780, ICI 182,780 + leptin, and leptin alone (Fig. 4). As expected, E<sub>2</sub> significantly (by ~50%) decreased the cytoplasmic expression of estrogen receptor  $\alpha$  and increased (by ~150%) its nuclear levels, relative to estrogen receptor  $\alpha$  under serum-free medium conditions. Also predictably, ICI 182,780 treatment induced the degradation of estrogen receptor  $\alpha$ , resulting in reduced estrogen receptor  $\alpha$  abundance in the cytoplasm and nucleus (~85 and 70%, respectively). These effects of ICI 182,780 were partially reversed in the presence of E<sub>2</sub> (Fig. 4). The addition of leptin to ICI 182,780-treated cells significantly improved nuclear estrogen receptor  $\alpha$  expression but had only minimal effects on the cytoplasmic estrogen receptor  $\alpha$  levels. Leptin alone had no significant effects on estrogen receptor  $\alpha$  expression in the cytoplasmic and nuclear compartments (Fig. 4).

The above observations were confirmed by fluorescence microscopy of estrogen receptor  $\alpha$  in MCF-7 cells treated with ICI 182,780 in the presence or absence of leptin. Estrogen receptor  $\alpha$  accumulated in the nucleus upon E<sub>2</sub> stimulation, whereas a 24-hour treatment with ICI 182,780 dramatically reduced nuclear estrogen receptor  $\alpha$  expression. The effect of ICI 182,780 was prevented by the addition of leptin (Fig. 4B).

**Leptin Increases Estrogen Receptor  $\alpha$  Recruitment to the pS2 Promoter in ICI 182,780-Treated MCF-7 Cells.** The function of nuclear estrogen receptor  $\alpha$  under different conditions was addressed with chromatin immunoprecipitation assay (Fig. 5). We found that the stimulation of MCF-7 cells with E<sub>2</sub> increased (~5-fold) the recruitment of estrogen receptor  $\alpha$  to the classical E<sub>2</sub>-responsive estrogen response element-containing pS2 gene promoter. This effect coincided with the greater association of polymerase II to the pS2 regulatory sequences (Fig. 5). In the presence of ICI 182,780, the recruitment of estrogen receptor  $\alpha$  to the pS2 promoter was similar to that

seen in untreated cells, and the recruitment of polymerase II was completely blocked. The addition of leptin counteracted the inhibitory action of ICI 182,780, resulting in a greater association of polymerase II (increased by ~2-fold) and estrogen receptor  $\alpha$  (~3-fold) to the pS2 promoter. Leptin alone did not stimulate the recruitment of either estrogen receptor  $\alpha$  or polymerase II to the pS2 promoter (Fig. 5).

**Effects of Leptin on Estrogen Receptor  $\alpha$  Transcriptional Activity in ICI 182,780-Treated MCF-7 Cells.** We validated the information obtained with chromatin immunoprecipitation assays using estrogen response element-luciferase reporter system (Fig. 6). In control experiments, E<sub>2</sub> significantly (by ~250%) stimulated estrogen response element-dependent transcription above the basal level, whereas the addition of ICI 182,780 to E<sub>2</sub> abolished this effect (Fig. 6). Leptin alone did not activate estrogen response element transcription above that seen under serum-free medium conditions. Similarly, leptin did not improve E<sub>2</sub>-dependent estrogen response element activation. In the presence of ICI 182,780, estrogen response element activity decreased ~60% below basal levels. In contrast, in ICI 182,780 + leptin cotreated cells, estrogen response element activity was increased ~50% above the level recorded in untreated cells (Fig. 6).


**Leptin Increases Estrogen Receptor  $\alpha$  Half-Life and Reduces Estrogen Receptor  $\alpha$  Ubiquitination in ICI 182,780-Treated MCF-7 Cells.** ICI 182,780 is known to induce rapid degradation of estrogen receptor  $\alpha$  in MCF-7 (46, 51). We probed the possibility that leptin treatment competes with ICI 182,780 action and increases estrogen receptor  $\alpha$  stability. Using pulse-chase assay, we confirmed previous observations that estrogen receptor  $\alpha$  half-life in untreated cells is ~4 hours, and in ICI 182,780-treated cells, ~1.5 hours (refs. 47 and 51; Fig. 7A). The addition of leptin increased estrogen receptor  $\alpha$  half-life to ~2.5 hours (Fig. 7A).

Next, we addressed the mechanism by which leptin might decrease estrogen receptor  $\alpha$  turnover. Because ICI 182,780- and E<sub>2</sub>-dependent degradation of estrogen receptor  $\alpha$  occurs through the ubiquitin-proteasome pathway (46, 47), we studied the effects of leptin on estrogen receptor  $\alpha$  ubiquitination (Fig. 7B). The ubiquitination of estrogen receptor  $\alpha$  was undetectable in untreated cells, whereas it was increased when the cells were treated for 1 hour with ICI 182,780 or E<sub>2</sub>. The addition of leptin greatly reduced estrogen receptor  $\alpha$  ubiquitination in ICI 182,780-treated cells (Fig. 7B). Leptin alone did not induce estrogen receptor  $\alpha$  ubiquitination. However, estrogen receptor  $\alpha$  ubiquitination was still observed when ICI 182,780 was challenged with E<sub>2</sub> (data not shown).

The above treatments had no effects on the expression and ubiquitination of  $\beta$ -catenin, a known target of proteasome (ref. 52; Fig. 7B; data not shown).

## DISCUSSION


Obesity is a risk factor for the development of breast cancer in postmenopausal women (1–4) and for tumor recurrence in all breast cancer patients, regardless of age and menopausal status (4). However, molecular mechanisms by which excessive fat accumulation could promote mammary carcinogenesis remain unknown. One possibility is that the process is mediated by



**Fig. 4** Leptin increases nuclear abundance of estrogen receptor  $\alpha$  ( $ER\alpha$ ) in ICI 182,780-treated MCF-7 cells. **A**, effects of leptin on subcellular estrogen receptor  $\alpha$  expression. MCF-7 cells were treated with 10 nmol/L  $E_2$ , 10 nmol/L ICI 182,780 (ICI),  $E_2$  + ICI 182,780 ( $E_2$ +ICI), 100 ng/mL leptin (LPT), or ICI 182,780 + leptin (ICI+LPT) for 24 hours or were left untreated (SFM). The expression of estrogen receptor  $\alpha$  was determined by Western blotting in 50  $\mu$ g of cytoplasmic or nuclear proteins. The expression of GAPDH (cytoplasmic enzyme) and nucleolin (nuclear protein) was assessed as a control of protein loading. The experiments were performed three times. The bars represent mean levels of estrogen receptor  $\alpha$  expression ( $\pm$ SEM). The differences between ICI 182,780 and ICI 182,780 + leptin values were statistically significant ( $P < 0.05$ ). **B**, fluorescence microscopy. The expression of estrogen receptor  $\alpha$  ( $ER$ ) was assessed by immunostaining and fluorescence microscopy in MCF-7 cells treated for 24 hours with 10 nmol/L  $E_2$ , 10 nmol/L ICI 182,780 (ICI), or 10 nmol/L ICI 182,780 + 100 ng/mL leptin (ICI+LPT) or left untreated in SFM. 4',6-Diamidino-2-phenylindole (DAPI) staining and bright field (BF) of the same fields is shown to visualize cell nuclei and general morphology. Magnification,  $\times 100$ .

elevated estrogen levels produced by adipose tissue in postmenopausal women (35, 53). In addition, it has been suggested that the development and progression of breast cancer could be stimulated by mitogenic and transforming activity of leptin (18), the levels of which rise proportionally to body mass index and are generally higher in women than in men (10). Furthermore,

because estrogen receptor  $\alpha$  and ObR have been found coexpressed in malignant mammary tissue and breast cancer cell lines (18–20), it is also possible, that both signaling systems are involved in a functional cross-talk contributing to carcinogenesis. However, leptin/ $E_2$  interactions and their possible role in breast cancer have not been extensively studied. In this work,



**Fig. 5** Leptin increases estrogen receptor  $\alpha$  recruitment to pS2 promoter in ICI 182,780-treated MCF-7 cells. The cells were treated for 4 hours with 10 nmol/L  $E_2$ , 10 nmol/L ICI 182,780 (ICI), 100 ng/mL leptin (LPT), ICI 182,780 + leptin (ICI+LPT),  $E_2$  + ICI 182,780 ( $E_2$ +ICI) or left untreated (SFM). The cells were then cross-linked with formaldehyde and lysed, and soluble, precleared chromatin was obtained. The soluble chromatin was immunoprecipitated with either the anti-estrogen receptor  $\alpha$  F-10 mAb (Santa Cruz Biotechnology; ChIP: ER $\alpha$ ) or the anti-polymerase II CTD4H8 mAb (UBI; ChIP: pol II). The estrogen receptor  $\alpha$  and polymerase II immunocomplexes were reverse cross-linked, and DNA was recovered by phenol/chloroform extraction and ethanol precipitation. The pS2 promoter sequences containing estrogen response element were detected by PCR with specific primers, as detailed in Materials and Methods. To control input DNA, pS2 promoter was amplified from 30  $\mu$ L of initial preparations of soluble chromatin (before immunoprecipitations).


we investigated whether the presence of leptin could compete with antiestrogenic effects produced by ICI 182,780.

First, we provided evidence that estrogen receptor  $\alpha$ -positive breast cancer cells MCF-7 and T47D express higher levels of ObR1 than estrogen receptor  $\alpha$ -negative cell lines MDA-MB-231 and MDA-MB-435. These results confirmed the data of other investigators who demonstrated ObR1 expression in T47D and MCF-7 cells (18–20) but lack of ObR1 mRNA in MDA-MB-231 cells (19). As a cellular model of this study, we selected estrogen receptor  $\alpha$ -positive and ICI 182,780-sensitive MCF-7 breast cancer cells. We demonstrated that MCF-7 cells respond to leptin stimulation with the activation of several signaling intermediates, including the STAT3, ERK1/2, and Akt pathways (Figs. 1 and 2). In MCF-7 cells, leptin was also able to inactivate the cell cycle inhibitor pRb and stimulate cell growth (Fig. 2). These results extend the observations of Xu *et al.* (18), Dieudonne *et al.* (19), Laud *et al.* (20), and Okamura *et al.* (22), who described leptin-dependent proliferation and leptin-induced STAT3 and ERK1/2 signaling in different estrogen receptor  $\alpha$ -positive breast cancer cell lines. The maximal mitogenic concentrations of leptin used in our and other studies (100 ng/mL) are in the range of serum leptin levels found in obese and morbidly obese (body mass index > 40) individuals (54, 55).


The growth of estrogen receptor  $\alpha$ -positive breast cancer cells can be effectively inhibited by ICI 182,780, which induces rapid proteasome-mediated degradation of estrogen receptor  $\alpha$  (44–46). We report here, for the first time, that antiestrogenic action of ICI 182,780 can be significantly reduced in the presence of leptin. Specifically, in ICI 182,780-treated MCF-7 cells, leptin increased estrogen receptor  $\alpha$  half-life and decreased estrogen receptor  $\alpha$  ubiquitination. These effects coincided with elevated nuclear estrogen receptor  $\alpha$  expression, increased estrogen receptor  $\alpha$  recruitment to the  $E_2$ -sensitive gene promoter, and increased estrogen response element-dependent transcrip-

tion. Leptin also counteracted cytostatic effects of ICI 182,780, resulting in increased cell proliferation (Figs. 3–7).

Interestingly, the mechanism by which leptin competes with ICI 182,780 appears to be different from that exerted by  $E_2$ . For instance, estrogen receptor  $\alpha$  is still ubiquitinated in ICI 182,780 +  $E_2$ -treated cells, whereas it is not ubiquitinated in ICI 182,780 + leptin-treated cells (Fig. 7B; data not shown). Similarly, the abundance of nuclear estrogen receptor  $\alpha$  is higher under ICI 182,780 + leptin conditions than that seen in ICI 182,780 +  $E_2$ -treated cells (Fig. 4A). In part, this phenomenon could be explained by the recent discovery that estrogen receptor  $\alpha$  turnover is differentially regulated depending on whether the receptor is unliganded, agonist bound, or antagonist bound and whether other cellular pathways (e.g., MAP kinases) are induced by cell surface receptors (46). Thus, it is possible that leptin can exert its action only on ICI 182,780-dependent estrogen receptor  $\alpha$  processing. Indeed, in different assays, we did not observe any effects of leptin on basal or  $E_2$ -induced activity of estrogen receptor  $\alpha$ . These data suggest that in our cell model, leptin did not modulate the synthesis of endogenous  $E_2$ . This latter point is worth discussion because leptin has been suggested as a potential modulator of  $E_2$  production (36–40). In some cell models (36, 37), including breast cancer cells (38), leptin has been shown to stimulate the aromatase gene promoter and aromatase activity. Furthermore, pharmacologic doses of



**Fig. 6** Leptin increases estrogen receptor  $\alpha$  transcription at estrogen response element promoters in ICI 182,780-treated cells. MCF-7 cells grown in 24-well plates were transfected for 6 hours with 0.5 mg of DNA per well using Fugene 6. All transfection mixtures contained 0.5 mg of estrogen response element reporter plasmid estrogen response element-TK-Luc. In addition, each of the DNA mixtures contained 50 ng of pRL-TK-Luc plasmid encoding renilla luciferase to assess transfection efficiency. Upon transfection, the cells were shifted to SFM for 16 hours and then treated for 24 hours with 10 nmol/L  $E_2$ , 10 nmol/L ICI 182,780 (ICI), 100 ng/mL leptin (LPT), ICI 182,780 + leptin (ICI+LPT),  $E_2$  + ICI 182,780 ( $E_2$ +ICI) or left untreated (SFM). Luciferase activity (Luc and RI Luc) was measured in cell lysates with a luminometer. Relative Luc activity in each sample was obtained upon normalization of Luc to RI-Luc values. The mean relative Luc activity ( $\pm$ SEM) obtained in five experiments is shown. The differences between leptin and ICI 182,780 values and between ICI 182,780 and leptin + ICI 182,780 values were statistically significant ( $P < 0.05$ ).



**Fig. 7** Leptin effects of estrogen receptor  $\alpha$  half-life and ubiquitination in ICI 182,780-treated MCF-7 cells. **A**, effects of leptin on estrogen receptor  $\alpha$  half-life. The half-life of estrogen receptor  $\alpha$  was determined by  $^{35}\text{S}$  pulse-chase labeling, as described in Materials and Methods. The abundance of estrogen receptor  $\alpha$  was analyzed at different time points (0, 2, 4, 6, and 8 hours) in untreated cells (SFM) and in cells treated with 10 nmol/L ICI 182,780 and 10 nmol/L ICI 182,780 + 100 ng/mL leptin (ICI+LPT). The expression of estrogen receptor  $\alpha$  at time 0 was assigned a value of 100. The relative estrogen receptor  $\alpha$  expression ( $\pm$ SEM) under different experimental conditions is presented in the graph. This experiment was repeated three times. The differences between ICI 182,780 and ICI 182,780 + leptin values were statistically significant ( $P < 0.05$ ) at 1, 2, and 4 hours. **B**, effects of leptin on estrogen receptor  $\alpha$  ubiquitination. MCF-7 cells were treated for 1 hour with 10 nmol/L  $\text{E}_2$ , 10 nmol/L ICI 182,780 (ICI), or 10 nmol/L ICI 182,780 + 100 ng/mL leptin (ICI+LPT) or left untreated in SFM. Estrogen receptor  $\alpha$  was immunoprecipitated (IP) from 500  $\mu\text{g}$  of total protein lysates, and its levels and ubiquitination were evaluated by Western blotting (WB) with specific Abs, as described in Materials and Methods. The expression of  $\beta$ -catenin ( $\beta\text{-cat}$ ) in 50  $\mu\text{g}$  of total protein lysates is shown as a control of protein loading.

leptin (1000 ng/mL) apparently activate estrogen response element promoters, presumably through the stimulation of  $\text{E}_2$  synthesis (56), however, increased  $\text{E}_2$  expression has not been formally shown in this setting. Our data included in Figs. 4A, 5, and 6 suggest that the exogenous  $\text{E}_2$  levels were similar in untreated and leptin-induced MCF-7 cell cultures.

In summary, we demonstrated that leptin interferes with the action of ICI 182,780 in MCF-7 cells. Our results suggest that the mechanism of this phenomenon involves increased nuclear expression and activity of estrogen receptor  $\alpha$  but is independent of  $\text{E}_2$ . Future studies should explore whether obesity might impede the benefits of ICI 182,780 therapy in breast cancer patients.

## REFERENCES

- Stephenson GD, Rose DP. Breast cancer and obesity: an update. *Nutr Cancer* 2003;45:1-16.
- Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin [review]. *Int J Oncol* 2002;21:1285-92.
- Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. *Proc Soc Exp Biol Med* 1997;216:28-43.
- Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *J Clin Oncol* 2002;20:1128-43.
- Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. *Ann Intern Med* 1994;120:18-25.
- Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D. Reduction of enhanced mammary carcinogenesis in LA/N-cp (corrupt) rats by energy restriction. *Proc Soc Exp Biol Med* 1991;196:381-4.
- Waxler SH. Obesity and cancer susceptibility in mice. *Am J Clin Nutr* 1960;8:760-6.
- Wolff GL, Kodell RL, Cameron AM, Medina D. Accelerated appearance of chemically induced mammary carcinomas in obese yellow

- (Avy/A) (BALB/c X VY) F1 hybrid mice. *J Toxicol Environ Health* 1982;10:131-42.
9. Heston WE, Vlahakis G. Genetic obesity and neoplasia. *J Natl Cancer Inst* (Bethesda) 1962;29:197-209.
  10. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. *Eur J Endocrinol* 2000;143:293-311.
  11. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. *J Mammary Gland Biol Neoplasia* 2002;7:49-66.
  12. Bonnet M, Delavaud C, Laud K, et al. Mammary leptin synthesis, milk leptin and their putative physiological roles. *Reprod Nutr Dev* 2002;42:399-413.
  13. Brann DW, Wade MF, Dhandapani KM, Mahesh VB, Buchanan CD. Leptin and reproduction. *Steroids* 2002;67:95-104.
  14. Goumenou AG, Matalliotakis IM, Koumantakis GE, Panidis DK. The role of leptin in fertility. *Eur J Obstet Gynecol Reprod Biol* 2003;106:118-24.
  15. Sierra-Honigsmann MR, Nat AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. *Science* 1998;281:1683-6.
  16. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. *FASEB J* 2000;14:2329-33.
  17. Tsuchiya T, Shimizu H, Horie T, Mori M. Expression of leptin receptor in lung: leptin as a growth factor. *Eur Pharmacol* 1999;365:273-9.
  18. Hu X, Juneja SC, Maible NJ, Cleary MP. Leptin: a growth factor in normal and malignant breast cells and for normal mammary gland development. *J Natl Cancer Inst* (Bethesda) 2002;94:1704-11.
  19. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. *Biochem Biophys Res Commun* 2002;293:622-8.
  20. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. *Mol Cell Endocrinol* 2002;188:219-26.
  21. Baratta M, Grolli S, Tamanini C. Effect of leptin in proliferating and differentiated HC11 mouse mammary cells. *Regul Pept* 2003;113:101-7.
  22. Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC- $\alpha$  and PPAR expression. *Biochim Biophys Acta* 2002;1592:107-16.
  23. Tartaglia LA. The leptin receptor. *J Biol Chem* 1997;272:6093-6.
  24. Barr VA, Lane K, Taylor SI. Subcellular localization and internalization of the four human leptin receptor isoforms. *J Biol Chem* 1999;274:21416-24.
  25. Sweeney G. Leptin signalling. *Cell Signalling* 2002;14:655-63.
  26. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. *FEBS Lett* 2003;546:45-50.
  27. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. *J Biol Chem* 1997;272:32686-95.
  28. Bjorbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. *J Biol Chem* 2001;276:4747-55.
  29. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG, Funanage VL. Leptin expression in human mammary epithelial cells and breast milk. *J Clin Endocrinol Metab* 1998;83:1810-3.
  30. Cleary MP, Phillips FC, Getzin SC, et al. Genetically obese MMTV-TGF- $\alpha$ /Lep(ob)Lep(ob) female mice do not develop mammary tumors. *Breast Cancer Res Treat* 2003;77:205-15.
  31. O'Brien SN, Welter BH, Price TM. Presence of leptin in breast cell lines and breast tumors. *Biochem Biophys Res Commun* 1999;259:695-8.
  32. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. *Int J Mol Med* 2000;5:421-6.
  33. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). *Cancer Causes Control* 2000;11:383-8.
  34. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. *Int J Cancer* 1999;80:523-6.
  35. Simpson ER. Sources of estrogen and their importance. *J Steroid Biochem Mol Biol* 2003;86:225-30.
  36. Magoffin DA, Weitsman SR, Agarwal SK, Jakimiuk AJ. Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. *Ginekol Pol* 1999;70:1-7.
  37. Kitawaki J, Kusuki I, Koshiha H, Tsukamoto K, Honjo H. Leptin directly stimulates aromatase activity in human luteinized granulosa cells. *Mol Hum Reprod* 1999;5:708-13.
  38. Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. *J Biol Chem* 2003;278:28668-76.
  39. Spicer LJ, Francisco CC. The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. *Endocrinology* 1997;138:3374-9.
  40. Ghizzoni L, Barreca A, Mastorakos G, et al. Leptin inhibits steroid biosynthesis by human granulosa-lutein cells. *Horm Metab Res* 2001;33:323-8.
  41. Machinal-Quelin F, Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. *Endocrine* 2002;18:179-84.
  42. Bennett PA, Lindell K, Karlsson C, Robinson IC, Carlsson LM, Carlsson B. Differential expression and regulation of leptin receptor isoforms in the rat brain: effects of fasting and oestrogen. *Neuroendocrinology* 1998;67:29-36.
  43. Lindell K, Bennett PA, Itoh Y, Robinson IC, Carlsson LM, Carlsson B. Leptin receptor 5' untranslated regions in the rat: relative abundance, genomic organization and relation to putative response elements. *Mol Cell Endocrinol* 2001;172:37-45.
  44. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. *Expert Rev Anticancer Ther* 2002;2:151-60.
  45. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. *Cancer* 2000;89:817-25.
  46. Marsaud V, Gougelet A, Maillard S, Renoir JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor  $\alpha$  (ER $\alpha$ ), differentially affect ER $\alpha$  extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. *Mol Endocrinol* 2003;17:2013-27.
  47. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)- $\alpha$  and essential for the antiproliferative activity of ICI 182,780 in ER $\alpha$ -positive breast cancer cells. *Mol Endocrinol* 2003;17:356-65.
  48. Salerno M, Sisci D, Mauro L, Guvakova M, Ando S, Surmacz E. Insulin receptor substrate 1 (IRS-1) is a target of a pure antiestrogen ICI 182,780 in breast cancer cells. *Int J Cancer* 1999;81:299-304.
  49. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGFIR) signaling pathway in breast cancer cells. *Cancer Res* 1997;57:2606-10.
  50. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 2000;103:843-52.
  51. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. *Proc Natl Acad Sci USA* 1992;89:4037-41.

52. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. *Cancer Biol Ther* 2002;1:337-41.
53. Bray GA. The underlying basis for obesity: relationship to cancer. *J Nutr* 2002;132(Suppl):S3451-5.
54. Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. *J Clin Invest* 1996;98:1277-82.
55. Van Dielen FMH, van'T Veer C, Buurman WA, Greve JWM. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. *J Clin Endocrinol Metab* 2002;87:1708-16.
56. Catalano S, Mauro L, Marsico S, et al. Leptin induces, via ERK1/2 signal, functional activation of estrogen receptor  $\alpha$  in MCF-7 cells. *J Biol Chem* 2004;279:19908-15.
57. Surmacz E, Burgaud J-L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. *Clin Cancer Res* 1995;1:1429-36.
58. Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDAMB-231 breast cancer cells. *Cancer Res* 2001;61:6747-54.